echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 4 + 7 "atorvastatin calcium tablet" passed the consistency evaluation

    4 + 7 "atorvastatin calcium tablet" passed the consistency evaluation

    • Last Update: 2019-11-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 20, Hunan Dino was approved according to the listing application of "atorvastatin calcium tablets" submitted by the new 4 categories, and it was deemed to have passed the consistency evaluation Hunan Dino became the fifth manufacturer to pass the consistency evaluation of atorvastatin calcium tablets after Jialin pharmaceutical, Xing'an pharmaceutical, Lepu pharmaceutical and Qilu pharmaceutical Atorvastatin is suitable for heterozygous or non familial hypercholesterolemia, mixed hyperlipidemia and homozygous hypercholesterolemia It is the first super heavyweight product with annual sales of more than 10 billion US dollars in the world It has opened the small molecule drug sales myth in the history of new drug research and development Since it was approved to be listed in early 1997 to the end of 2018, the cumulative sales revenue has reached US $164.43 billion, which is currently the highest cumulative sales of drugs It is also the great demand of the market that makes atorvastatin calcium tablets enter a new stage, that is, volume purchase Carlin pharmaceutical's Arle is the first product in China to pass the consistency evaluation In December 2018, the results of "4 + 7" urban volume procurement were released, and Carlin pharmaceutical won the bid at a low price In March 2019, the "4 + 7" urban volume procurement began to be officially implemented As the traditional advantage market of Pfizer Lipitor, the impact of volume procurement policy has been strongly impacted by generic drugs After Fujian Province followed up "4 + 7" in June, Lipitor directly fell out of the top 20 sales volume of the province from the top three in the month of implementation According to the health performance report of Dezhan, the market share of Carlin pharmaceutical's Arle in the sample hospitals of 11 pilot cities has increased significantly, nearly 68%, which has surpassed Lipitor to become the largest brand of atorvastatin market share On September 24, 25 provincial alliance regions started to purchase with volume, and Lepu, Xing'an and Qilu won the bid, leaving Jialin behind and dissolving the sales team Now the fifth company in Hunan Dino has passed the consistency evaluation, which is bound to occupy a place in the future competition of purchasing with volume In addition, 11 other companies are still conducting the consistency evaluation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.